- Netflix cancels ‘Jessica Jones’ and ‘The Punisher’ 5 Months Ago
- YouTube is fueling the rise in flat earth believers 5 Months Ago
- Review: Crackdown 3 is not a world worth saving Today 11:00 AM
- Scathing privacy report calls Facebook a ‘digital gangster’ Today 10:50 AM
- 21 Savage goes deep on 21 Savage memes Today 10:49 AM
- Everyone is debating the number of towels you should own Today 10:47 AM
- How to unlock the Fortnite Prisoner stage 4 skin Today 10:45 AM
- Julian Assange reportedly nominated for Nobel Peace Prize Today 10:27 AM
- Major U.S. airlines will soon implement nonbinary gender options Today 10:21 AM
- Trump calls 25th Amendment talk a ‘coup’ attempt Today 8:42 AM
- The Hatebook: Inside Facebook’s thriving subculture of racism Today 7:29 AM
- Anthony Hamilton’s national anthem at All-Star game sparks MVP meme Today 7:02 AM
- ‘Subtle Asian Dating’ is the un-Tinder we all need right now Today 5:00 AM
- Man delighted to find 30-year-old computer still works Sunday 5:32 PM
- Report: Google used shell companies to build data centers, obtain tax breaks Sunday 3:38 PM
It’s unclear if young blood even makes a difference.
A startup called Ambrosia Medical plans to open its first clinic in New York City later this year, and it has an unusual aim: to fill patient veins with blood from more youthful donors.
For $8,000, Ambrosia Medical patrons can undergo a procedure that gives them an infusion of young blood, according to Business Insider. The belief is that in doing this, it can help slow the aging process, giving new life to old organs. The idea has also been parodied on TV in the HBO show Silicon Valley.
Ambrosia Medical conducted a clinical trial in the U.S. in 2017 studying whether this theory is accurate, but the results of that trial haven’t been made public yet. Still, company founder Jesse Karmazin told Business Insider that the results so far have been “really positive.” Anecdotally, recipients felt like they had better sleep, focus, and memory following a transfusion of young blood, as well as improved muscle tone. Those claims are not yet backed up with data, though.
Since Ambrosia Medical is giving patents a blood transfusion (or a plasma transfusion, specifically), a procedure approved by the FDA, it doesn’t face a unique or difficult approval process before opening its doors. According to CDC data, more than 14.5 million blood transfusions take place each year, and typically, recipients don’t experience any ill effects. However, proof from clinical trials could help boost business, adoption, and interest in the idea of using young blood to rejuvenate the older body.
Thus far, David Cavalier, Ambrosia’s chief operating officer, says that Ambrosia Medical has had about 150 patients, 81 of which participated in its clinical trial. Recipients have ranged in age from 35 to 92, while blood donors range in age from 16 to 25.
Ambrosia Medical’s website, which went live last week, is sparse. It consists primarily of a list of addresses where interested parties can email for more information, or you can be added to a waitlist to undergo an $8,000 transfusion.
H/T Business Insider
Christina Bonnington is a tech reporter who specializes in consumer gadgets, apps, and the trends shaping the technology industry. Her work has also appeared in Gizmodo, Wired, Refinery29, Slate, Bicycling, and Outside Magazine. She is based in the San Francisco Bay Area and has a background in electrical engineering.